EPO mRNA(N1-Me-pUTP) - BioReagent,Integrity of mRNA ≥85% (CE);1.0 mg/mL

Cat. No.: E1506462
Disponível para encomenda
GRAU & PUREZA BioReagent ? BioReagent grade — tested suitable for life-science and molecular-biology use. Use for cell culture, assays, and biochemical work needing biological compatibility. Integrity of mRNA ≥85% (CE);1.0 mg/mL
Synonyms
hEPO mRNA(Cap1, m1Ψ)|hEPO mRNA (N1-Me-Pseudo UTP)
Storage
Store at -20°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
★
Tamanho
Alemanha (EU)
USA*
Preço
Qtd
100μg
E1506462-100μg
—
5 Em stock
216,85€
10×100μg
E1506462-10×100μg
Sob encomenda · 8–12 semanas
1119,30€
Enter a quantity for the sizes you want to add.

Especificações

Sinónimos
hEPO mRNA(Cap1, m1Ψ) | hEPO mRNA (N1-Me-Pseudo UTP)
Especificações e pureza
BioReagent,Integrity of mRNA ≥85% (CE);1.0 mg/mL
Estabilidade e armazenamento
Store at -20℃~-80℃ long term (24 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
Condições de armazenamento de armazenamento
Store at -20°C,Avoid repeated freezing and thawing
Enviado em
Ice chest + Ice pads
Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.
Grau
BioReagent
Product Line
Produtos biológicos

Dados avançados

Certificados(CoA,COO,BSE/TSE e Mapa de Análise)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

1 results found

Lot NumberCertificate TypeDataItem
ZJ25F1230667ZJ25F1230667Certificate of AnalysisDec 29, 2025 E1506462
FAQs e artigos
Calculadoras de soluções
Revisões

Avaliações dos Clientes

Application Protocols

No vendor-validated protocols are provided for this specific SKU; the following are general, field-tested workflows for mRNA reagents.

  • Reconstitution (general):

    1. Thaw on ice. Briefly spin down.
    2. Reconstitute in nuclease-free water or low-ionic-strength buffer (e.g., 5–10 mM sodium citrate, pH 6.4–7.0) to desired concentration.
    3. Aliquot into single-use volumes; store at −20 °C. Avoid repeated freeze–thaw.
  • Lipid-based transfection (24-well format, example):

    1. Dilute mRNA to 10–100 ng/µL in RNase-free buffer.
    2. Prepare transfection reagent per manufacturer’s instructions in serum-free medium.
    3. Combine to achieve recommended N/P or reagent:mass ratio; incubate 10–20 min at RT.
    4. Add complexes dropwise to cells (50–80% confluency). Incubate 4–6 h, then replace with complete medium.
    5. Collect supernatants at 24–72 h; quantify EPO by ELISA.
  • Electroporation (example):

    1. Wash cells and resuspend in electroporation buffer.
    2. Mix 1–10 µg mRNA with cells; transfer to cuvette on ice.
    3. Pulse using device-optimized settings; recover cells in pre-warmed medium.
  • Integrity check:

    • Analyze a small aliquot by agarose gel/CE; quantify by A260.

These steps are general guidance and should be optimized per cell type and delivery system.

Biological Roles
  • Item-specific (Product Data):

    • Encodes: Erythropoietin (EPO) mRNA (species origin not specified; refer to CoA/Spec Sheet).
  • EPO biology (general/literature):

    • EPO is a secreted glycoprotein hormone that binds the EPO receptor (EPOR), activating JAK2/STAT5 and other pathways to regulate erythroid progenitor survival and differentiation.
    • EPO is heavily glycosylated; glycan composition influences secretion, stability, and receptor interactions. Expression from mRNA in different host cells can yield distinct glycoforms useful for structure–function studies.
    • Cellular processing: Classical secretion pathway through ER/Golgi; quality control involves chaperones and glycosylation enzymes. Overexpression can probe ER capacity and unfolded protein response.
  • Modified mRNA considerations (general):

    • N1-methyl-pseudouridine substitution reduces innate immune activation through TLRs and RIG-I–like receptors in many systems and can improve translation efficiency and mRNA stability.
    • 5′ capping and poly(A) tail length (not specified for this item) modulate translation initiation and decay pathways (eIF4F recruitment, PABP binding).
  • Experimental readouts (general):

    • Secreted EPO quantification by ELISA from culture supernatants.
    • Downstream signaling: STAT5 phosphorylation as a surrogate of autocrine/paracrine activity in EPOR-expressing models.

No medical or clinical claims are intended; content is for research use in biochemical and cellular systems.

Buffer Applications

This section addresses buffer choices relevant to reconstitution, storage, and delivery of mRNA.

  • Item-specific (Product Data):

    • Storage: −20 °C; avoid repeated freeze–thaw.
    • Specific buffer composition: Not specified for this item; refer to CoA/Spec Sheet.
  • Reconstitution and storage buffers (general/literature):

    • RNase-free water is suitable for initial dissolution. For enhanced stability, low-ionic-strength buffers (e.g., 1–10 mM sodium citrate, pH 6.4–7.0) can mitigate hydrolysis; include chelators at low levels if compatible.
    • Avoid high concentrations of divalent cations (Mg2+, Ca2+) during storage; they catalyze RNA cleavage. If needed for translation, add immediately before use.
    • Optional excipients for freeze–thaw resilience (research practice): trehalose or sucrose (5–10%) can help during lyophilization or −80/−20 °C storage; validate for your application.
  • Working buffers for delivery (general):

    • Lipid-mediated transfection: Use serum-free, RNase-free buffers during complex formation; transition to complete medium after complexation per reagent guidance.
    • Electroporation: Low-conductivity proprietary buffers or isotonic RNase-free solutions per device recommendations.
  • Practical tips:

    • Aliquot to single-use volumes (e.g., 5–20 µL) to eliminate refreezing.
    • Thaw on ice; gently mix—avoid vortexing to prevent shearing.
    • Use certified RNase/DNase-free consumables and filter tips.
Green Alternatives

While this product is an aqueous biopolymer rather than a traditional chemical solvent or reagent, sustainability considerations still apply.

  • Lower environmental burden (general):

    • Aqueous handling: Typically prepared and used in water or mild buffers, reducing reliance on volatile organic solvents.
    • Room-temperature operations: Many steps (mixing, transfection complex formation) occur at ambient temperature, minimizing energy use apart from cold storage.
  • Considerations and tradeoffs (general):

    • Cold chain: −20 °C storage and ice shipping increase energy demand and packaging waste.
    • Single-use plastics: RNase-free workflows can generate significant plastic waste (tubes, tips, filters).
  • Greener practice suggestions (general):

    • Optimize aliquot sizes to reduce thaw cycles and waste.
    • Use recyclable/returnable cold-shipping materials where available; consolidate orders to reduce shipments.
    • Employ RNase-free, low-bind consumables from suppliers with take-back or recycling programs.
    • Replace DEPC where possible with modern, less hazardous RNase-inactivation strategies.
  • Alternative experimental designs (general):

    • Use DNA transfection or viral vectors for long-term expression to reduce repeated mRNA shipments, when scientifically appropriate; note these alternatives have their own biosafety and waste profiles.

These points are general guidance for greener lab operations and are not item-specific specifications.

Pharmaceutical Uses

No therapeutic or clinical claims are made for this product. The information below describes common research and development contexts for mRNA in pharmaceutical sciences.

  • Item-specific (Product Data):

    • Grade: BioReagent; For research use only.
  • R&D and formulation roles (general/literature):

    • Platform evaluation: Benchmark lipid nanoparticle (LNP), polymeric, or peptide-based delivery systems using a secreted reporter protein (EPO) to quantify expression kinetics in vitro.
    • Process development studies: Assess mRNA stability during sterile filtration, fill–finish, and cold-chain stress testing.
    • Analytical method development: Calibrate ELISAs, LC-MS glycoform profiling, and cap/poly(A) analytical workflows using a defined mRNA payload.
    • Compatibility screening: Study excipient effects (buffers, salts, sugars, antioxidants) on mRNA integrity and translation in preclinical research settings.
  • Regulatory notes (general):

    • Research-grade materials are not intended for human administration or diagnostic procedures. For GMP manufacturing or clinical development, materials with appropriate quality system controls, release testing, and documentation are required.
  • Handling guidance relevant to pharm sci labs:

    • Maintain RNase-free environments; qualify storage and shipping conditions; monitor integrity by CE or agarose gel and A260-based assays.
Physical Properties
  • Item-specific (Product Data):

    • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular weight (full-length transcript): Not specified for this item; refer to CoA/Spec Sheet.
    • Storage: Store at −20 °C; avoid repeated freezing and thawing.
  • Typical physical properties for IVT mRNA (literature/general):

    • Physical state: Aqueous solution or lyophilized solid depending on formulation; highly water-soluble due to polyanionic phosphate backbone.
    • UV absorbance: Strong at 260 nm; A260/A280 ~2.0 is indicative of RNA purity (literature, not a specification for this item).
    • Stability: Sensitive to hydrolysis (particularly alkaline conditions) and RNase-mediated degradation; stability enhanced by low temperatures, RNase-free conditions, and presence of stabilizing salts/sugars (e.g., sodium citrate, trehalose) when applicable.
    • pKa: Not meaningful for entire polymer; phosphate diesters are fully ionized at physiological pH (literature).
    • Solubility: Readily soluble in nuclease-free water and low-ionic-strength buffers; precipitation can occur with alcohols or in the presence of high concentrations of polycations (literature).
  • Practical implications (general):

    • Handle on ice; minimize time at room temperature.
    • Avoid divalent cations (Mg2+, Ca2+) unless used immediately for translation, as they can catalyze RNA hydrolysis.
    • Use RNase-free plastics, reagents, and filtered tips to preserve integrity.
Quality and Grades
  • Item-specific (Product Data):

    • Grade/Purity: BioReagent.
  • What BioReagent typically implies (general explanation):

    • Suitable for biological research applications requiring low bioburden and low nuclease contamination, but not certified for clinical or diagnostic use.
    • Emphasis on functionality in cell-based assays, transfection, and in vitro translation rather than analytical chromatography purity metrics used for small molecules.
  • Quality attributes commonly assessed for IVT mRNA (general/literature; not specifications for this item):

    • Integrity: Assessed by agarose gel electrophoresis or capillary electrophoresis (RIN-like measures), absence of truncated species.
    • Identity: Confirmation of sequence, cap structure, and poly(A) tail length.
    • Residuals: Low residual dsRNA, template DNA, enzymes, and salts; dsRNA can impact innate immune sensing.
    • UV purity: A260/A280 and A260/A230 ratios.
  • Stabilizers and formulation notes:

    • Stabilizers (e.g., sodium citrate buffer, chelators, sugars) may be used in some mRNA formulations to enhance storage stability; composition is not specified for this item—refer to CoA/Spec Sheet.
  • Documentation:

    • For specific acceptance criteria (e.g., length, capping efficiency, tail length, residual impurities), consult the product’s CoA/Spec Sheet.
Reaction and Applications
  • Item-specific (Product Data):

    • Application text not provided; use cases below are general for EPO-encoding, N1-methyl-pseudouridine–modified mRNA.
  • Core applications (general/literature):

    • Transient expression studies: Deliver EPO mRNA to mammalian cells to study secretion, glycosylation, and post-translational processing of EPO without genomic integration.
    • In vitro translation: Use cell-free systems to synthesize EPO protein for biochemical assays and standards.
    • Pathway interrogation: Probe ER stress, JAK/STAT signaling, and feedback regulation following EPO overexpression in relevant cell models.
    • Formulation research: Benchmark LNPs, polymer carriers, or electroporation parameters using a secreted glycoprotein readout (EPO ELISA) as a functional metric.
  • Role of N1-methyl-pseudouridine (general):

    • Literature reports show reduced innate immune sensing, increased ribosomal throughput, and improved mRNA stability versus unmodified uridine, often enhancing protein yield.
  • Practical guidance:

    • Use RNase-free technique; pre-warm transfection reagents as directed by vendor.
    • Titrate mRNA dose (e.g., 10–500 ng per well in 24-well plates; scale by cell type and carrier) and measure secreted EPO over 24–72 h.
    • Verify EPO expression via ELISA of supernatants and Western blot of cell lysates; assess glycoforms if relevant (EPO is heavily glycosylated).
Reaction Conditions

As a biological reagent, “reaction conditions” here refer to typical conditions for delivery and expression workflows. Values below are general literature guidance and not specifications for this item.

  • Cell transfection (general):

    • Cells: Common mammalian lines (e.g., HEK293, HeLa, CHO) or primary cells.
    • Dose: Often 10–500 ng mRNA per well (24-well), 0.5–2 µg per well (6-well); optimize per cell type and reagent.
    • Carrier: Lipid-based transfection reagents or polymeric systems; form complexes in serum-free buffer for 10–20 min at RT.
    • Incubation: 4–6 h complex exposure followed by media change; measure secreted EPO at 24–72 h.
    • Temperature: 37 °C, 5% CO2 for mammalian cells.
  • Electroporation (general):

    • Buffers: Vendor-specific, low-conductivity; keep mRNA on ice before pulsing.
    • Amounts: 1–10 µg per 100 µL cuvette are typical starting points depending on cell density and device settings; titrate to minimize cytotoxicity.
  • In vitro translation (general):

    • Systems: Rabbit reticulocyte lysate, wheat germ, or human cell–derived systems.
    • Additives: Mg2+ and K+ per kit recommendations; RNase inhibitor to protect input mRNA.
    • Readout: SDS-PAGE/Western blot for EPO; note that complex glycosylation is not reproduced in prokaryotic or lysate systems lacking ER/Golgi.
  • Analytical controls:

    • Integrity check by agarose gel or CE before use; quantify by A260 (1 A260 ≈ 40 µg/mL RNA—literature approximation).
    • Include mock-transfected and carrier-only controls.
Safety and Handling
  • Item-specific (Product Data):

    • GHS Classification, Signal Word, H-Statements, Pictograms: Not specified for this item; refer to SDS.
    • Shipping: Ice chest + ice pads.
    • Storage: Store at −20 °C; avoid repeated freeze–thaw.
  • General guidance for RNA handling (literature/practice):

    • PPE: Laboratory coat, gloves (change frequently to avoid RNase contamination), safety glasses.
    • Engineering controls: Work in a clean area; optional use of a designated RNase-free biosafety cabinet to minimize contamination.
    • Incompatibilities: RNases (ubiquitous on skin and surfaces), alkaline solutions (promote 2′-OH transesterification), high temperatures, and metal-catalyzed hydrolysis.
    • Decontamination: Use RNase-inactivating solutions for surfaces and equipment; bake glassware if needed.
    • First aid (general): Non-hazardous biopolymer under typical lab conditions; in case of contact, rinse with water. Inhalation of aerosols or ingestion should be avoided; seek medical attention per institutional policy and SDS.
  • Special risks and mitigations:

    • Avoid aerosol generation; keep tubes closed.
    • Use nuclease-free water and reagents only; include RNase inhibitors where appropriate.
    • Aliquot upon receipt to eliminate repeated freeze–thaw cycles, which fragment RNA and reduce transfection performance.

Always consult the product’s SDS and institutional EHS guidance for authoritative safety information.

Solvent Selection

This product is a nucleic acid reagent, not a solvent. Selection focuses on reconstitution and handling buffers rather than organic solvent choice.

  • Item-specific (Product Data):

    • No specific buffer or concentration provided; refer to CoA/Spec Sheet for formulation details.
  • Recommended media for mRNA (general/literature):

    • Primary: RNase-free water (nuclease-free), optionally with low-ionic-strength buffering (e.g., 1–10 mM sodium citrate, pH ~6.4–7.0) to reduce hydrolysis; avoid Tris at elevated temperatures for long-term storage due to primary amine reactivity.
    • Working solutions: RNase-free PBS without Mg2+/Ca2+ or buffers compatible with the chosen transfection method; add RNase inhibitor when appropriate.
    • Avoid: Alcohols (precipitation), strong bases, and polyvalent cations that promote degradation.
  • Miscibility and polarity (general):

    • Highly water-soluble; insoluble in nonpolar organic solvents.
  • Practical selection tips:

    • Match ionic strength and pH to downstream application (e.g., electroporation often prefers low-conductivity buffers; lipid-based delivery tolerates physiological buffers).
    • Filter sterilize (0.22 µm) only if validated not to shear long mRNA; generally prepare under aseptic, RNase-free conditions instead of post-filtration.
Storage and Reconstitution
  • Item-specific (Product Data):

    • Storage conditions: Store at −20 °C; avoid repeated freezing and thawing.
    • Shipping: Ice chest + ice pads.
  • Reconstitution (general/literature):

    • Thaw on ice. If lyophilized or concentrated, dissolve/dilute in nuclease-free water or a low-ionic-strength buffer (e.g., 1–10 mM sodium citrate, pH 6.4–7.0). Mix gently—do not vortex vigorously.
    • Concentration determination: Measure A260 (1 A260 ≈ 40 µg/mL RNA; literature approximation). Verify integrity by agarose gel or CE if critical.
  • Aliquoting and handling:

    • Prepare single-use aliquots (e.g., 5–20 µL) to prevent freeze–thaw cycles that cause strand breaks and reduce expression.
    • Store working aliquots at −20 °C; for extended storage, −80 °C is commonly used in research settings (general guidance; not a specification for this item).
    • Maintain RNase-free environment: RNase-free consumables, gloves, and surface decontamination.
  • Short-term use:

    • Keep on ice during setup. Limit room-temperature exposure.
  • Compatibility notes:

    • Avoid buffers with high divalent cation content for storage; add Mg2+ only immediately before in vitro translation if needed.

For item-specific formulation, concentration, cap structure, and poly(A) tail details, consult the CoA/Spec Sheet.

Structure and Identity

Brief overview: This product is an in vitro–transcribed messenger RNA (mRNA) encoding erythropoietin (EPO) that incorporates N1-methyl-pseudouridine triphosphate (N1-Me-pUTP) in place of uridine to enhance performance in cellular systems.

  • Item-specific (Product Data):

    • Product name: EPO mRNA (N1-Me-pUTP)
    • SKU: E1506462
    • Grade: BioReagent
    • CAS, CID, InChIKey, SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular formula, Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Structural description (general/literature):

    • Linear, single-stranded RNA composed of ribonucleotides, with N1-methyl-pseudouridine replacing uridine residues (extent of substitution and pattern are typically global during IVT; confirm on CoA).
    • Expected domains for functional mRNA constructs (literature): 5′ untranslated region (5′ UTR), open reading frame (ORF) for EPO, 3′ UTR, and a poly(A) tail; 5′ cap and tail length are formulation-dependent (not specified for this item).
    • Functional groups: phosphate backbone (polyanion), ribose sugars (2′-OH), nucleobases including modified N1-methyl-pseudouridine.
    • Stereochemistry: D-ribose units in standard β-N-glycosidic linkages; chiral phosphorus not applicable in backbone linkage mixture for mRNA (natural phosphodiester linkages).
  • Identity considerations (general):

    • Sequence-defined biopolymer; identity typically verified by sequence information, cap analysis, poly(A) tail length, agarose gel or CE profiling, and mass/UV data—see CoA for item-specific verification.
Synthetic Utility

This product is a finished mRNA reagent rather than a small-molecule synthon. Traditional organic synthesis utility does not apply. The following points focus on molecular biology “synthetic” workflows.

  • Not typically applicable (item-specific):

    • No small-molecule functional group transformations are relevant.
  • Applicable molecular biology utility (general):

    • Acts as a transient template for protein biosynthesis in cells or in cell-free translation systems, enabling rapid prototyping of expressed proteins without DNA cloning or genomic editing.
    • Useful as a positive control payload when optimizing mRNA capping strategies, poly(A) tail lengths, and modified nucleotide content in IVT processes.
    • Serves as a benchmark for delivery technology comparisons (LNP vs polymer vs electroporation) by tracking secreted EPO titers.
  • Retrosynthetic/construct design perspective (general):

    • Elements influencing performance include UTR selection, Kozak context, signal peptide for secretion, codon optimization, cap structure (Cap 1 vs Cap 0), and tail length. These are not specified for this item; consult CoA for exact construct details if provided.
Target Specificity
  • Item-specific (Product Data):

    • Target gene/protein: Erythropoietin (EPO) as encoded by the mRNA construct.
    • Species, isoform, sequence details: Not specified for this item; refer to CoA/Spec Sheet.
  • General notes (literature):

    • EPO contains a signal peptide directing secretion; mature human EPO is a glycoprotein of ~30–34 kDa depending on glycosylation.
    • Functional specificity is mediated through the EPO receptor (EPOR); downstream signaling primarily via JAK2/STAT5.
  • Experimental implications:

    • Verify species matching if your downstream assays (e.g., ELISA, bioassays) are species-specific.
    • Confirm presence of a secretion signal in the ORF if secreted expression is required; consult the CoA/Spec Sheet for construct details if available.

Perguntas frequentes

What does BioReagent mean?
BioReagent indicates that the product has been processed and tested for biological and biochemical applications. Specifications may include endotoxin limits, microbial controls, sterility, low DNase/RNase/protease activity, and verified biological activity where relevant.
How should this product be stored?
Store at ?20 °C. Avoid repeated freeze–thaw cycles. Aliquot into single-use volumes before freezing.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Precisa de ajuda para escolher o grau?

O nosso guia de seleção de graus abrange pureza, estado do estabilizador e adequação à aplicação para todas as variantes do nosso catálogo.

Ver o guia de graus BioReagent →

Deseja que lhe enviemos uma mensagem quando tivermos descontos disponíveis?

Lembrar-me mais tarde

Obrigado! Por favor, verifique a sua caixa de entrada de e-mail para confirmar.

Ops! As notificações estão desativadas.